Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
11.00
0.00 (0.00%)
At close: Dec 12, 2025, 4:00 PM EST
11.22
+0.22 (2.00%)
After-hours: Dec 12, 2025, 7:30 PM EST
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,596,410
Market Cap
22.83M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CVKD News
- 15 hours ago - Cadrenal's Quiet Expansion Play Is Starting to Get Loud - Accesswire
- 16 hours ago - Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - Accesswire
- 1 day ago - Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) - GlobeNewsWire
- 11 days ago - Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - GlobeNewsWire
- 23 days ago - Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award - GlobeNewsWire
- 4 weeks ago - Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - GlobeNewsWire
- 3 months ago - Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors - GlobeNewsWire